Syracuse

4′-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication

Archive ouverte

Sourimant, Julien | Lieber, Carolin | Aggarwal, Megha | Cox, Robert | Wolf, Josef | Yoon, Jeong-Joong | Toots, Mart | Ye, Chengin | Sticher, Zachary | Kolykhalov, Alexander | Martinez-Sobrido, Luis | Bluemling, Gregory | Natchus, Michael | Painter, George | Plemper, Richard

Edité par CCSD ; American Association for the Advancement of Science (AAAS) -

International audience. Preparing antiviral defenses Antiviral drugs are an important tool in the battle against COVID-19. Both remdesivir and molnupiravir, which target the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase, were first developed against other RNA viruses. This highlights the importance of broad-spectrum antivirals that can be rapidly deployed against related emerging pathogens. Sourimant et al . used respiratory syncytial virus (RSV) as a primary indication in identifying further drugs that target the polymerase enzyme of RNA viruses. The authors explored derivatives of molnupiravir and identified 4′ fluorouridine (EIDD-2749) as an inhibitor of the polymerase of RSV and SARS-CoV-2. This drug can be delivered orally and was effective against RSV in mice and SARS-CoV-2 in ferrets. —VV

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion